Adverse Event Reporting

The Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006 (DSNDCPA) requires every dietary supplement marketer in the United States to (1) include a domestic address or phone number on the label for consumer adverse event reporting, (2) maintain records of all adverse event reports received for at least six years, and (3) report every Serious Adverse Event (SAE) to FDA within 15 business days using MedWatch Form 3500A submitted through the FDA Safety Reporting Portal. Reports flow into the CFSAN Adverse Event Reporting System (CAERS), the publicly searchable database used by FDA for cluster detection, signal generation and prioritisation.

A Serious Adverse Event is any adverse event resulting in death, life-threatening experience, inpatient hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect, or — based on reasonable medical judgement — requiring medical or surgical intervention to prevent any of the foregoing. Non-serious adverse events must be recorded and retained but are not subject to mandatory submission; they constitute the trending and signal-detection dataset. The 15-business-day clock starts on the date the marketer (or any agent including customer service, retailer partners or contract manufacturers) receives the report — internal routing delay does not extend the clock.

AER intake reaches the marketer through multiple channels: the label-mandated phone or address, customer service email and web, retailer partner forwarding (Amazon, Walmart, Costco, pharmacy chains), healthcare professional reports, poison control centres, plaintiff law firm intake, and social media. Defensible intake captures reporter contact (with consent for follow-up), product and lot identification, event description, onset and duration, concomitant products and medications, outcome and causality assessment. The reporter does not need to be a healthcare professional and the report does not need to be independently verified for the reporting obligation to be triggered. Failure patterns include routing complaints separately from adverse events such that the AER never reaches pharmacovigilance, missing the 15-day clock through slow internal triage, and treating AER intake as a customer service function rather than a quality and regulatory function. Enforcement responses to missed or late reporting include Warning Letters, civil penalties, FDA-483 inspections at records sites and, in egregious cases, criminal referral.